This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1′ residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.